CLB Obesity: Prevention Strategies, Treatment Paradigms, and Research Needs for 2016 and Beyond

Program: Corporate Liaison Board Forum: Obesity - Prevention Strategies, Treatment Paradigms, and Research Needs for 2016 and Beyond
Clinical/Translational Session
Friday, April 1, 2016: 4:45 PM-6:15 PM
Room 153 (BCEC)
Sponsored by the Corporate Liaison Board of the Endocrine Society

Chair:
John Germak, MD, Novo Nordisk Inc, Princeton, NJ

Sponsored by the Corporate Liaison Board of the Endocrine Society, this yearly forum highlights the collaboration between industry, academia, and healthcare agencies from both government and non-government organizations in approaches to treatment of endocrine disorders. Enhance your ENDO 2016 experience with this special session. Speakers representing clinical science and industry will discuss current science and future research for preventing and treating obesity.

4:45 PM

John Germak, MD, Global Medical Affairs, Shire
Disclosure Not Provided: JG
4:50 PM

Michael W. Schwartz, MD, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA
Disclosure Not Provided: MWS
5:10 PM

Kevin L. Grove, PhD, Novo Nordisk Inc.
Disclosures:
KLG: Vice President, Novo Nordisk.
5:30 PM

Jack Adam Yanovski, MD, PhD, Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD
Disclosures:
JAY: Principal Investigator, Zafgen, Inc..
5:50 PM

John Germak, MD, Global Medical Affairs, Shire
Disclosure Not Provided: JG